## AMENDMENTS TO THE CLAIMS:

The following listing replaces all prior versions of the claims:

1-16. (Canceled)

17. (Currently amended) A method for the treatment and prophylaxis of respiratory diseases, allergic diseases, asthma and/or chronic obstructive pulmonary diseases comprising the step of administering loteprednol or a pharmaceutically acceptable ester thereof and N-(3,5-dichloropyridin-4-yl)-2-[1-(4-fluorobenzyl)-5-hydroxyindol-3-yl]-2-oxoacetamide (DFHO) or a pharmaceutically acceptable salt thereof to a subject in need of treatment.

- 18. (Previously presented) The method as claimed in claim 17, wherein administration is oral.
- 19. (Previously presented) The method as claimed in claim 17, wherein administration is topical.
- 20. (Previously presented) The method as claimed in claim 17, wherein the loteprednol or pharmaceutically acceptable ester thereof and N-(3,5-dichloropyridin-4-yl)-2-[1-(4-fluorobenzyl)-5-hydroxyindol-3-yl]-2-oxoacetamide (DFHO) or pharmaceutically acceptable salt thereof are administered simultaneously, sequentially or separately from one another, intranasally or by inhalation.
- 21. (Previously presented) The method as claimed in claim 17, wherein the loteprednol or pharmaceutically acceptable ester thereof and N-(3,5-dichloropyridin-4-yl)-2-[1-(4-fluorobenzyl)-5-hydroxyindol-3-yl]-2-oxoacetamide (DFHO) or pharmaceutically acceptable salt thereof are administered as an inhalable liquid or solid preparation.
- 22. (Previously presented) The method as claimed in claim 17, wherein one of the loteprednol or pharmaceutically acceptable ester thereof and N-(3,5-dichloropyridin-4-yl)-2-[1-(4-fluorobenzyl)-5-hydroxyindol-3-yl]-2-oxoacetamide (DFHO) or pharmaceutically acceptable salt thereof is administered orally and one is administered topically.

Applicants: Mathias LOCHER et al.

Application No.: 10/523,802 Attorney Docket No. 42804-212835

23. (Previously presented) The method as claimed in claim 17, wherein the N-(3,5-dichloropyridin-4-yl)-2-[1-(4-fluorobenzyl)-5-hydroxyindol-3-yl]-2-oxoacetamide (DFHO) or pharmaceutically acceptable salt thereof is administered orally.